secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERU INC. (VERU)
CIK:        0000863894
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001193125-23-141365
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veru Q2 net loss $38.8M ($0.48/share); revenue falls to $6.6M; FDA agrees on sabizabulin Phase 3 design
--------------------------------------------------------------------------------

- Net loss $38.8M vs $14.2M YoY; operating loss $39.4M including $3.9M impairment and $3.9M credit loss provision.
- Revenue down to $6.6M from $13.0M; gross profit $4.1M vs $11.2M; R&D expense rose to $22.9M.
- Cash and equivalents $23.5M at March 31, 2023, down from $80.2M at September 30, 2022.
- FDA agreed on confirmatory Phase 3 trial for sabizabulin in COVID-19 ARDS; 408-subject, two interim efficacy analyses planned.
- Sold ENTADFI for $20M plus up to $80M milestones; Lincoln Park Capital committed up to $100M common stock purchase.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/863894/000119312523141365/0001193125-23-141365-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/863894/000119312523141365/d466660d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-141365

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer